Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03289195 | Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer | active not recruiting | N/A | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT02783664 | Evaluating the Effects of Genetic Testing on Patients' Stress Levels | active not recruiting | — | 164 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 |
| clinicaltrials |
| NCT04009044 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | active not recruiting | Phase 2 | 156 | Northwestern UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT01203839 | Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer | active not recruiting | Phase 2 | 110 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02393794 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 / Phase 2 | 51 | Priyanka SharmaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy(ASCENT-07) | active not recruiting | Phase 3 | 654 | Gilead SciencesINDUSTRY | 28 | Oct 3, 2025 | clinicaltrials |
| NCT00989638 | A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer | active not recruiting | — | 305 | University of ChicagoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT02826434 | Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201389 | CARE (Chemotherapy Alopecia REduction)(CARE) | active not recruiting | N/A | 30 | George Washington UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05036252 | Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity | active not recruiting | — | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05654532 | Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 1 | 100 | Accutar Biotechnology IncINDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03581136 | Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod | active not recruiting | N/A | 74 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05160545 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 1 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05339685 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors | active not recruiting | Phase 1 | 82 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02562118 | Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 40 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04520269 | A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) | active not recruiting | Phase 1 / Phase 2 | 74 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04280536 | Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA) | active not recruiting | Phase 1 / Phase 2 | 86 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07185334 | Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating in Patients With Breast Cancer(FluoropolyMesh) | active not recruiting | N/A | 100 | Saint Petersburg State University, RussiaOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03283384 | Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.(NEOLBC) | active not recruiting | Phase 2 | 100 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03820063 | Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study(TRAIN-3) | active not recruiting | Phase 2 | 462 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04763915 | Improving Care After Inherited Cancer Testing(IMPACT) | active not recruiting | N/A | 720 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02889874 | EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer(EXPERT) | active not recruiting | N/A | 1,167 | Breast Cancer Trials, Australia and New ZealandOTHER | 9 | Sep 18, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04088708 | Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors(ROME) | active not recruiting | N/A | 126 | University of Alabama at BirminghamOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03515798 | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer(PELICAN) | active not recruiting | Phase 2 | 52 | Institut Paoli-CalmettesOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT04273542 | Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening(ICRG0101) | active not recruiting | N/A | 1,100 | Centre Jean PerrinOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06303154 | Evaluation of Mobiderm Intimate Bra in the Management of Breast Edema Related to Breast Cancer Treatment(MOBIBRA) | active not recruiting | N/A | 30 | ThuasneINDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06522971 | Effects of Physical Exercise on Response to Treatement in Breast Cancer(CancerBeat) | active not recruiting | N/A | 55 | Latvian Biomedical Research and Study CentreOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03585621 | Stereotactic Body Radiation Therapy for Breast Cancer | active not recruiting | N/A | 24 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04759248 | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer(ATREZZO) | active not recruiting | Phase 2 | 55 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05063786 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)(ALPHABET) | active not recruiting | Phase 3 | 27 | Spanish Breast Cancer Research GroupOTHER | 6 | Sep 8, 2025 | clinicaltrials |
| NCT04812652 | Digitally Distributed Yoga for Women Treated for Breast Cancer(DigiyogaCare) | active not recruiting | N/A | 229 | Region Örebro CountyOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07154771 | Development and Usability Evaluation of an Arm Circumference Measurement Tool For Patients Undergoing Breast Surgery | active not recruiting | N/A | 35 | Saglik Bilimleri Universitesi Gulhane Tip FakultesiOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02608216 | [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer | active not recruiting | Phase 1 | 20 | University of PennsylvaniaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07149636 | Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women(HBM-BSE) | active not recruiting | — | 3,000 | Peking Union Medical College HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04134598 | ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer(EUROPA) | active not recruiting | Phase 3 | 926 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05629065 | Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)((PATH-SIC)) | active not recruiting | N/A | 800 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06253182 | Psychosexual Educational Partners Program (PEPP)(PEPP) | active not recruiting | N/A | 60 | The University of Tennessee, KnoxvilleOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03165487 | Comparison of the Breast Tumor Microenvironment | active not recruiting | — | 14 | Columbia UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05258539 | Breast Cancer Prevention and Screening Membership(AdDePi_KS) | active not recruiting | N/A | 189 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06599216 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer | active not recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03216421 | Intraoperative Radiation Therapy (IORT) in DCIS | active not recruiting | N/A | 265 | Columbia UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06198751 | A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | active not recruiting | Phase 2 | 104 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT03958136 | Clinico-biological Data Collection Study of Metastatic Breast Cancer(EPICURE_SEIN) | active not recruiting | N/A | 289 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2025source: clinicaltrials